Bristol-Myers Squibb: all 2,184 studies

Page 6 of 22. Open to participants first (162), then studies with results posted, then the rest; newest registration first within each.

• An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsCompletedNCT01968109Phase 1/2Results posted
• Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)CompletedNCT01964430Phase 3Results posted
• Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid TumorsCompletedNCT01962103Phase 1/2Results posted
• Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line SettingCompletedNCT01946477Phase 2Results posted
• Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)CompletedNCT01938001Phase 3Results posted
• A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsCompletedNCT01928394Phase 1/2Results posted
• Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic MelanomaCompletedNCT01927419Phase 2Results posted
• Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) MutationCompletedNCT01915498Phase 1/2Results posted
• PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)TerminatedNCT01891643Phase 3Results posted
• Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled SyringeCompletedNCT01890473Phase 1Results posted
• Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)CompletedNCT01884350Phase 4Results posted
• Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement SurgeryCompletedNCT01884337Phase 4Results posted
• Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)CompletedNCT01881230Phase 2/3Results posted
• Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIVTerminatedNCT01866930Phase 3Results posted
• Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 DiabetesCompletedNCT01864174Phase 4Results posted
• Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic ArthritisCompletedNCT01860976Phase 3Results posted
• Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular ResponseCompletedNCT01850004Phase 2Results posted
• Methotrexate-Inadequate Response Autoinjector Device Sub StudyCompletedNCT01844895Phase 3Results posted
• Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)CompletedNCT01844518Phase 3Results posted
• Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)CompletedNCT01844505Phase 3Results posted
• Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With CobicistatCompletedNCT01837719Phase 1Results posted
• Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT01836029Phase 2Results posted
• Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).CompletedNCT01835587Phase 1/2Results posted
• Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in JapanCompletedNCT01835470Phase 3Results posted
• Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal ImpairmentCompletedNCT01830205Phase 1Results posted
• A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-BasedCompletedNCT01820572Phase 3Results posted
• Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant RecipientsCompletedNCT01791491Phase 2Results posted
• Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)CompletedNCT01783938Phase 2Results posted
• Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary FibrosisCompletedNCT01766817Phase 2Results posted
• Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy VolunteersCompletedNCT01766050Phase 4Results posted
• Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete RemissionCompletedNCT01757535Phase 3Results posted
• Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney DiseaseTerminatedNCT01752985Phase 2Results posted
• Safety and Efficacy Study in Subjects With Chronic HCV and Underlying HemophiliaCompletedNCT01741545Phase 3Results posted
• Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT01734928Phase 3Results posted
• A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphomaCompletedNCT01724177Phase 2Results posted
• Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic MelanomaCompletedNCT01721772Phase 3Results posted
• Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic RegimensCompletedNCT01721759Phase 2Results posted
• A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)CompletedNCT01721746Phase 3Results posted
• Efficacy and Safety Study of Abatacept to Treat Lupus NephritisTerminatedNCT01714817Phase 3Results posted
• A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid TumorsCompletedNCT01714739Phase 1/2Results posted
• Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaCompletedNCT01712789Phase 3Results posted
• Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced MelanomaTerminatedNCT01709162Phase 2Results posted
• A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01698801Phase 2Results posted
• Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant MelanomaTerminatedNCT01696045Phase 2Results posted
• Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric PatientsCompletedNCT01691794Phase 4Results posted
• Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced MelanomaCompletedNCT01681212Phase 2Results posted
• Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLCCompletedNCT01673867Phase 3Results posted
• Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced MelanomaCompletedNCT01673854Phase 2Results posted
• Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)CompletedNCT01668784Phase 3Results posted
• VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT01666444Phase 2Results posted
• Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to ImatinibCompletedNCT01660906Phase 4Results posted
• An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedNCT01658878Phase 1/2Results posted
• Efficacy and Safety Study of Ozanimod in Ulcerative ColitisCompletedNCT01647516Phase 2Results posted
• Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)CompletedNCT01642004Phase 3Results posted
• Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaCompletedNCT01632150Phase 2Results posted
• Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C VirusCompletedNCT01628692Phase 2Results posted
• Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis PatientsCompletedNCT01628393Phase 2/3Results posted
• PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaCompletedNCT01621490Phase 1Results posted
• Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TCTerminatedNCT01620944Phase 3Results posted
• Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian CancerCompletedNCT01611558Phase 2Results posted
• Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic SyndromeCompletedNCT01599325Phase 2Results posted
• Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With TelaprevirCompletedNCT01598090Phase 3Results posted
• Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to ImatinibCompletedNCT01593254Phase 2Results posted
• An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaCompletedNCT01592370Phase 1/2Results posted
• An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line ChemotherapyCompletedNCT01585987Phase 2Results posted
• Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.TerminatedNCT01571635Phase 2Results posted
• The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)CompletedNCT01566695Phase 3Results posted
• Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung DiseaseTerminatedNCT01559129Phase 2Results posted
• Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With RuxolitinibTerminatedNCT01523171Phase 2Results posted
• Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg IpilimumabCompletedNCT01515189Phase 3Results posted
• Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF MutationTerminatedNCT01514864Phase 2Results posted
• Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus InfectionCompletedNCT01492426Phase 3Results posted
• Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaCompletedNCT01478048Phase 2Results posted
• Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular LymphomaCompletedNCT01476787Phase 3Results posted
• Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)CompletedNCT01472081Phase 1Results posted
• Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV VirusCompletedNCT01471574Phase 3Results posted
• Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung CancerTerminatedNCT01471197Phase 2Results posted
• Pediatric Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT01460160Phase 2Results posted
• A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)CompletedNCT01456039Phase 1/2Results posted
• Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)CompletedNCT01454102Phase 1Results posted
• Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy AloneCompletedNCT01450761Phase 3Results posted
• Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis CCompletedNCT01448044Phase 3Results posted
• Biomarker Study of Elotuzumab in High Risk Smoldering MyelomaCompletedNCT01441973Phase 2Results posted
• Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers SquibbCompletedNCT01439204Phase 1Results posted
• Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir TrialsCompletedNCT01438424Phase 2Results posted
• Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With MyelofibrosisTerminatedNCT01437787Phase 3Results posted
• Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus TrialsCompletedNCT01428063Phase 2Results posted
• Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy SubjectsCompletedNCT01404572Phase 1Results posted
• Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)TerminatedNCT01400451Phase 1Results posted
• Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal FunctionCompletedNCT01393964Phase 1Results posted
• Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed FormulationsCompletedNCT01392703Phase 1Results posted
• BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis CCompletedNCT01389323Phase 3Results posted
• Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of CareCompletedNCT01359644Phase 2Results posted
• A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid LeukemiaCompletedNCT01358734Phase 2Results posted
• Phase I Biomarker Study (BMS-936558)CompletedNCT01358721Phase 1Results posted
• Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)TerminatedNCT01357655Phase 2Results posted
• BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)CompletedNCT01354431Phase 2Results posted
• A Rollover Study for Patients Who Participated in Other Romidepsin ProtocolsCompletedNCT01353664Phase 2Results posted
• Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on HemodialysisCompletedNCT01340586Phase 1Results posted
• Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric PatientsCompletedNCT01335698Phase 3Results posted

← Bristol-Myers Squibb overview and focus areas